



COPY OF PAPERS  
ORIGINALLY FILED

0300

3

#3

PTO/SB/21 (08-00)

Please place a plus sign (+) inside this box → ☐

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

5

Application Number

10/017,066

Filing Date

December 14, 2001

First Named Inventor

Arthur B. RAITANO

Group Art Unit

To Be Assigned

Examiner Name

To Be Assigned

Attorney Docket No.

511582002410

## ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment / Reply

☐ After Final

☐ Affidavits/declarations

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Information Disclosure Statement;  
PTO form 1449

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/  
Incomplete Application

☐ Response to Missing Parts  
under 37 CFR 1.52 or 1.53

☐ Assignment Papers  
(for an Application)

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a  
Provisional Application

☐ Power of Attorney, Revocation  
Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) \_\_\_\_\_

☐ After Allowance Communication to  
Group

☐ Appeal Communication to Board of  
Appeals and Interferences

☐ Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please identify  
below): Return postcard

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm

or

Individual Name

Kate H. Murashige

Registration No. 29,959

Signature

*Kate H. Murashige*

Date


March 26, 2002

## CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on March 26, 2002.

*Garee A. Haney*  
Garee A. Haney

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



COPY OF PAPERS  
ORIGINALLY FILED

PATENT  
Docket No. 511582002410

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on March 26, 2002.

*Garee A. Haney*  
Garee A. Haney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Arthur B. RAITANO et al.

Serial No.: 10/017,066

Filing Date: December 14, 2001

For: PHOR-1: A NOVEL G PROTEIN-  
COUPLED RECEPTOR UP-  
REGULATED IN PROSTATE CANCER

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/680,728, filed October 5, 2000, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \* is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of \* is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 511582002420. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 26, 2002

Respectfully submitted,

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125

Form PTO-1449 <div style="border: 1px solid black; border-radius: 50%; padding: 10px; width: 150px; float: left; margin-right: 10px;">           INFORMATION DISCLOSURE CITATION            BY AN APPLICATION            APR 04 2002            PATENT &amp; TRADEMARK OFFICE         </div> (Use several sheets if necessary)				Docket Number 511582002410		Application Number 10/017,066	
Applicant Arthur B. RAITANO et al.				Filing Date December 14, 2001		Group Art Unit To Be Assigned	
Mailing Date March 26, 2002							

U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	1.	12/1996	WO 96/39435	WIPO			
	2.	02/1999	WO 99/06550	WIPO			
	3.	01/2000	WO 00/04149	WIPO			
	4.	04/2000	WO 00/20590	WIPO			

OTHER DOCUMENTS <span style="float: right;">(including author, title, Date, Pertinent Pages, Etc.)</span>							
Examiner Initials	Ref. No.	Title					
	5.	Bepler et al., Genomics (1999) 55(2):164-175					
	6.	EMBL Sequence Accession No. A06681.Gcg_Geneseq_D, June 13, 2000 (first entry)					
	7.	EMBL Sequence Accession No. AF101565, January 29, 1999, November 8, 2000					
	8.	Hubert et al., Proc. Natl. Acad. Sci. USA (1999) 96(25):14523-14528					
	9.	Klein et al., Nat. Med. (1997) 3:402					
	10.	NAGENESEQ, EMBL Sequence Accession No. X40518, June 18, 1999 (first entry)					
	11.	Pinto et al., Clin. Cancer Res. (1996) 2(9):1445-1451					
	12.	Reiter et al., Proc. Natl. Acad. Sci. USA (1998) 95:1735					
	13.	Sjogren, Immunotechnology (1997) 3(3):161-172					
	14.	Su et al., Proc. Natl. Acad. Sci. USA (1996) 93:7252					

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.